OncoMatch/Clinical Trials/NCT07229313
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Is NCT07229313 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies KIVU-107 for advance solid tumors.
Treatment: KIVU-107 — This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antibody-drug conjugate
Exception: with topoisomerase 1 inhibitor payload
Prior treatment with any ADC with topoisomerase 1 inhibitor payload
Cannot have received: PTK7-targeted therapy
Any PTK7 - targeted therapy
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate kidney function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify